These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10690519)

  • 1. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55.
    Durrant LG; Maxwell-Armstrong C; Buckley D; Amin S; Robins RA; Carmichael J; Scholefield JH
    Clin Cancer Res; 2000 Feb; 6(2):422-30. PubMed ID: 10690519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.
    Buckley DT; Robins AR; Durrant LG
    Hum Antibodies Hybridomas; 1995; 6(2):68-72. PubMed ID: 7492753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
    Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
    Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7.
    Durrant LG; Buckley TJ; Denton GW; Hardcastle JD; Sewell HF; Robins RA
    Cancer Res; 1994 Sep; 54(18):4837-40. PubMed ID: 8069847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.
    Maxwell-Armstrong CA; Durrant LG; Buckley TJ; Scholefield JH; Robins RA; Fielding K; Monson JR; Guillou P; Calvert H; Carmichael J; Hardcastle JD
    Br J Cancer; 2001 Jun; 84(11):1443-6. PubMed ID: 11384090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody.
    Robins RA; Denton GW; Hardcastle JD; Austin EB; Baldwin RW; Durrant LG
    Cancer Res; 1991 Oct; 51(19):5425-9. PubMed ID: 1913661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
    Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.
    Durrant LG; Buckley DJ; Robins RA; Spendlove I
    Int J Cancer; 2000 Jan; 85(1):87-92. PubMed ID: 10585589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
    Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
    Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
    Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
    Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity.
    Durrant LG; Buckley DJ; Spendlove I; Robins RA
    Hybridoma; 1997 Feb; 16(1):23-6. PubMed ID: 9085124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7.
    Maxwell-Armstrong CA; Durrant LG; Robins RA; Galvin AM; Scholefield JH; Hardcastle JD
    Gut; 1999 Oct; 45(4):593-8. PubMed ID: 10486371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
    Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
    Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases.
    Elkord E; Dangoor A; Drury NL; Harrop R; Burt DJ; Drijfhout JW; Hamer C; Andrews D; Naylor S; Sherlock D; Hawkins RE; Stern PL
    J Immunother; 2008; 31(9):820-9. PubMed ID: 18833005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.
    Pilla L; Squarcina P; Coppa J; Mazzaferro V; Huber V; Pende D; Maccalli C; Sovena G; Mariani L; Castelli C; Parmiani G; Rivoltini L
    Cancer Res; 2005 May; 65(9):3942-9. PubMed ID: 15867395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody.
    Denton GW; Durrant LG; Hardcastle JD; Austin EB; Sewell HF; Robins RA
    Int J Cancer; 1994 Apr; 57(1):10-4. PubMed ID: 8150527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas.
    Cózar JM; Canton J; Tallada M; Concha A; Cabrera T; Garrido F; Ruiz-Cabello Osuna F
    Cancer Immunol Immunother; 2005 Sep; 54(9):858-66. PubMed ID: 15887015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.